Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 5/20 | 0.58 |
| ▸ | ABL1 | P00519 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8342310 | 0.91 | MMP12 (0.59) | MMP12ABL1MAPTMMP13POLB | |
| SCHEMBL6875530 | 0.89 | MMP12 (0.58) | MMP12ABL1MMP13POLBALDH1A1 | |
| SCHEMBL6450855 | 0.88 | MMP12 (0.55) | MMP12ABL1MMP13SCN10AEPHX2 | |
| SCHEMBL6879609 | 0.87 | MMP12 (0.54) | MMP12ABL1MAPTMMP13POLB | |
| SCHEMBL6879537 | 0.83 | MMP12 (0.55) | MMP12ABL1MAPTMMP13POLB | |
| SCHEMBL6875475 | 0.83 | MMP12 (0.52) | MMP12ABL1MAPTMMP13POLB | |
| SCHEMBL8342633 | 0.83 | MMP12 (0.52) | MMP12ABL1MAPTMMP13POLB | |
| SCHEMBL6463245 | 0.81 | MMP12 (0.56) | MMP12ABL1MMP13SCN10AALDH1A1 | |
| SCHEMBL6881932 | 0.79 | MMP12 (0.59) | MMP12ABL1MAPTMMP13POLB | |
| SCHEMBL6882916 | 0.79 | MMP12 (0.55) | MMP12ABL1MAPTMMP13POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | WARNER-LAMBERT COMPANY LLC | 2004-04-15 | — | — | US | claimed |
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | WARNER-LAMBERT COMPANY LLC | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | MMP11, MMP13, CBR1 | MMP12 7/4885ABL1 2800/4885MAPT 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.